The invention features compounds, pharmaceutical compositions and methods for treating patients who have an EGFR-driven cancer of Formula I: ##STR00001##
wherein the variables are as defined herein.

The present application relates to a polycyclic compound including nitrogen and an organic light emitting device including the same.

The present application relates to a polycyclic compound including nitrogen and an organic light emitting device including the same.

Provided are an additive for an electrolyte of a lithium battery; an electrolyte having the same; and a lithium battery using the electrolyte. The additive for an electrolyte of a lithium battery includes a triazine triphosphonate compound.

Provided are an additive for an electrolyte of a lithium battery; an electrolyte having the same; and a lithium battery using the electrolyte. The additive for an electrolyte of a lithium battery includes a triazine triphosphonate compound.

Trisubstituted triazines having the formula: ##STR00001## wherein: X is O and n is 0 or 1, Y is OH, NH.sub.2 or CH.sub.2NH.sub.2, Q is P, P═O, CH or N, when Q is P, R is phenyl, when Q is P═O, Z is R or OR, and R is alkyl or phenyl, when Q is CH, Z is PO(R).sub.2 or PO(OR).sub.2, when Q is N, Z is R, and their uses as epoxy and cyclic carbonate polymer curing agents.

Trisubstituted triazines having the formula: ##STR00001## wherein: X is O and n is 0 or 1, Y is OH, NH.sub.2 or CH.sub.2NH.sub.2, Q is P, P═O, CH or N, when Q is P, R is phenyl, when Q is P═O, Z is R or OR, and R is alkyl or phenyl, when Q is CH, Z is PO(R).sub.2 or PO(OR).sub.2, when Q is N, Z is R, and their uses as epoxy and cyclic carbonate polymer curing agents.

Organic electroluminescent device comprising an anode, a cathode, at least one emission layer and an organic semiconducting layer; wherein the organic semiconducting layer is arranged between the at least one emission layer and the cathode; wherein the organic semiconducting layer comprises; a) a first organic compound comprising a first C.sub.10 to C.sub.42 arene structural moiety and/or a first C.sub.2 to C.sub.42 heteroarene structural moiety, wherein i) the dipole moment of the first organic compound, computed by the TURBOMOLE V6.sub..5 program package using hybrid functional B3LYP and Gaussian 6-.sub.31G* basis set, is from 0 to 2.5 Debye; and ii) the LUMO energy level of the first organic compound in the absolute scale taking vacuum energy level as zero, computed by the TURBOMOLE V6.sub..5 program package using hybrid functional B.sub.3LYP and Gaussian 6-.sub.31G* basis set, is in the range from −1.7 eV to −2.1 eV; and b) a second organic compound comprising a second C.sub.10 to C.sub.42 arene structural moiety and/or a second C.sub.2 to C.sub.42 heteroarene structural moiety and in addition at least one polar group selected from phosphine oxide and phosphine sulfide, wherein in) the dipole moment of the second organic compound, computed by the TURBOMOLE V6.sub..5 program package using hybrid functional B.sub.3LYP and Gaussian 6-.sub.31G* basis set, is from 1.5 to 10 Debye; and iv) the LUMO energy level of the second organic compound in the absolute scale taking vacuum energy level as zero is less than 0.25 eV higher or lower than the LUMO energy level of the first organic compound; wherein it is provided that the first organic compound and the second organic compound are different from each other.

Disclosed are a heterocyclic compound and an organic light emitting device including the same.

Disclosed are a heterocyclic compound and an organic light emitting device including the same.